PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study
Study context
- Population
- Patients with acute coronary syndrome (ACS) and multiple lesions after percutaneous coronary intervention (PCI) for the culprit lesionplanned enrolment
- Participants
- 1,212 patients
- Planned comparison
- PCSK9 inhibitor plus high-intensity statin vs high-intensity statin monotherapy
- Primary endpoint
- Composite of:
- CV death
- MI
- Stroke
- Re-hospitalisation due to ACS or HF
- Any ischaemia-driven coronary revascularisation
- Follow-up
- 1-year follow-up
Methodological detailsstudy protocol, double-blind, placebo-controlled, multicentre, stratified randomisation, Protocol only; no results reported, Safety endpoints: PCSK9 inhibitor and statin intolerance
- Study protocol
- Double-blind
- Placebo-controlled
- Multicentre
- Stratified randomisation
- Protocol only; no results reported
- Safety endpoints: PCSK9 inhibitor and statin intolerance
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
PCSK9 inhibitor added to high-intensity statin therapy to prevent cardiovascular events in patients with acute coronary syndrome after percutaneous coronary intervention: a randomized, double- blind, placebo-controlled, multicenter SHAWN study. Am Heart J. Published 27 June 2024. doi:10.
Summarised from the published abstract; every number is checked against it